On February 25, 2025 Etcembly reported a new partnership with leading antibody manufacturer Vector Laboratories, Inc., using our AI platform EMLy to develop novel immunotherapeutics (Press release, Etcembly, FEB 25, 2025, View Source [SID1234650525]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Manufacturing problems such as poor yield and aggregation are significant issues in the development and production of antibody-based therapeutics.

In this partnership, we’ll be using EMLy’s cutting edge structural modelling and generative AI capabilities to redesign existing non-proprietary antibodies, creating optimised variants with enhanced manufacturability and improved therapeutic outcomes.

Our CEO, Michelle Teng, says:

"We’re excited to apply our AI-driven technology to Vector’s expertise in antibody engineering. This partnership will test different antibody variants and generate functional data, creating a powerful synergy that will advance cancer and autoimmune research."

Lisa V Sellers (Lisa V. S.) CEO of Vector Laboratories, adds:

"We’re excited to work with the Etcembly team to test optimized protein sequences and determine if their proprietary EMLy platform can enable us to improve them further for more effective therapies."